Skip to main content
. 2019 Dec 21;13(2):221–232. doi: 10.1016/j.tranon.2019.09.013

Figure 1.

Figure 1

Combination of BRD4 and PLK1 inhibition has synergistic antitumoral effects in pediatric tumor cell lines. A Combination indices (CI) of 16 pediatric tumor cell lines treated with varying concentrations of Volasertib and MK-8628 as well as combination of both agents for 72 h. B Comparison of combination indices in cell lines with high and low MYC and/or MYCN expression. C Heatmap of synergy score and excess over Bliss analysis of combination treatment with MK-8628 and Volasertib in MYCN-amplified neuroblastoma cell line IMR5 and rhabdomyosarcoma cell line RH30. D Heatmap of synergy score and excess over Bliss analysis of combination treatment with MK-8628 and GSK461364 in MYCN-amplified neuroblastoma cell line IMR5 and rhabdomyosarcoma cell line RH30.